Viewing data from:

ESTARYLLA

ANDA

ETHINYL ESTRADIOL; NORGESTIMATE | A090794 | XIROMED PHARMA ESPANA SL

1 strength0 unique patents0 unique exclusivities

Medicare Part D Spending

CMS annual spending data for Estarylla (2023)

Total Spending

$363K

Total Claims

12,957

Beneficiaries

3,423

Avg Cost/Unit

$0.51

Spending Trend

$243K(2019)→$344K(2020)→$403K(2021)→$380K(2022)→$363K(2023)

YoY Change:-6.6%

5yr CAGR:-1.5%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

Products (1)

#001 — 0.035MG;0.25MG

0 patents0 exclusivities▴

TABLET;ORAL-28 | Approved: Jan 30, 2013

No patent or exclusivity listings for this strength.